BBVA USA’s Biogen BIIB Stock Holding History

BBVA USA’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$29K	Sell	103 -12	-10%	-$3.93K	﹤0.01%	736
2021 Q2	$40K	Buy	+115	New	+$34.8K	﹤0.01%	705

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BBVA USA's BIIB Position: Q3 2021 in Review

BBVA USA reduced its Biogen (BIIB) stake by 10% in Q3 2021, selling an estimated $3.93K and leaving 103 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #736.

BBVA USA first reported a position in BIIB in Q2 2021 and has held it in 2 quarters since. The position peaked at $40K in Q2 2021. 1,039 funds tracked by Wall St. Rank hold BIIB as of Q3 2021.

BBVA USA held 103 shares of Biogen worth $29K as of Q3 2021.
BBVA USA sold 12 Biogen shares in Q3 2021, an estimated $3.93K.
Biogen made up ﹤0.01% of BBVA USA's portfolio in Q3 2021, its #736 holding.
BBVA USA first reported a position in Biogen in Q2 2021 and has held it in 2 quarters since.
BBVA USA's Biogen position peaked at $40K in Q2 2021.
1,039 funds tracked by Wall St. Rank held Biogen as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.